Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.39 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.39 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.39 |
| ▸ | TTR | P02766 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 9/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29767970 | 1.00 | HTT (0.39) | HTTMAPTSMN1; SMN2TP53PKM | |
| SCHEMBL26675364 | 0.88 | HTT (0.42) | HTTMAPTSMN1; SMN2TP53PKM | |
| SCHEMBL29767947 | 0.88 | HTT (0.42) | HTTMAPTSMN1; SMN2TP53PKM | |
| SCHEMBL26675382 | 0.86 | ALOX15 (0.45) | HTTMAPTSMN1; SMN2TP53PKM | |
| SCHEMBL30600527 | 0.86 | ALOX15 (0.45) | HTTMAPTSMN1; SMN2TP53PKM | |
| SCHEMBL29768164 | 0.82 | ENPP3 (0.40) | HTTMAPTSMN1; SMN2TP53PKM | |
| SCHEMBL26675446 | 0.82 | ENPP3 (0.40) | HTTMAPTSMN1; SMN2TP53PKM | |
| SCHEMBL26675292 | 0.80 | ELANE (0.41) | HTTMAPTSMN1; SMN2TP53PKM | |
| SCHEMBL29767959 | 0.80 | ELANE (0.41) | HTTMAPTSMN1; SMN2TP53PKM | |
| SCHEMBL26908761 | 0.79 | HCRTR2 (0.33) | HTTMAPTSMN1; SMN2TP53PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630549-B2 | Pyrazoleamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2026-05-19 | — | — | US | claimed |
| US-20230382911-A1 | PYRAZOLEAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-11-30 | — | — | US | claimed |
| US-12630549-B2 | Pyrazoleamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2026-05-19 | — | — | US | disclosed |
| EP-4284797-A1 | PYRAZOLEAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2023-12-06 | — | — | EP | disclosed |
| US-20230382911-A1 | PYRAZOLEAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230382911-A1 | PYRAZOLEAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230382911-A1 | PYRAZOLEAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382911-A1 | PYRAZOLEAMIDE DERIVATIVES | P2RY1, P2RX1, P2RX5 | HTT 4269/4885MAPT 3058/4885SMN1; SMN2 4421/4885 |
| US-12630549-B2 | Pyrazoleamide derivatives | CYP11B2, CYP11B1, ADRA1B | HTT 3987/4885MAPT 2409/4885SMN1; SMN2 2210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.